

1 **Title: T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of**  
2 **long COVID**

3 **One Sentence Summary:** Adaptive immunity is altered in patients with neurologic  
4 manifestations of long COVID.

5 **Authors:** Lavanya Visvabharathy<sup>1\*¶</sup>, Barbara A. Hanson<sup>1</sup>, Zachary S. Orban<sup>1</sup>, Patrick H. Lim<sup>1</sup>,  
6 Nicole M. Palacio<sup>2</sup>, Millenia Jimenez<sup>1</sup>, Jeffrey R. Clark<sup>1</sup>, Edith L. Graham<sup>1</sup>, Eric M. Liotta<sup>1</sup>,  
7 George Tachas<sup>3</sup>, Pablo Penaloza-MacMaster<sup>2</sup>, Igor J. Koralnik<sup>1\*</sup>

8 **Affiliations:** <sup>1</sup>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine,  
9 Northwestern University, Chicago IL 60611 USA

10 <sup>2</sup>Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern  
11 University, Chicago IL 60611 USA

12 <sup>3</sup>Director, Drug Discovery & Patents, Antisense Therapeutics Ltd., Melbourne, Australia

13

14 \*Corresponding authors: Igor J. Koralnik, M.D.: [igor.koralnik@northwestern.edu](mailto:igor.koralnik@northwestern.edu);  
15 Lavanya Visvabharathy, Ph.D: [lavanya.visvabharathy@northwestern.edu](mailto:lavanya.visvabharathy@northwestern.edu)

16 ¶ Lead contact: Lavanya Visvabharathy, Ph.D

17 **Abstract**

18 Many people experiencing long COVID syndrome, or post-acute sequelae of SARS-CoV-2  
19 infection (PASC), suffer from debilitating neurologic symptoms (Neuro-PASC). However,  
20 whether virus-specific adaptive immunity is affected in Neuro-PASC patients remains poorly  
21 understood. We report that Neuro-PASC patients exhibit distinct immunological signatures  
22 composed of elevated humoral and cellular responses toward SARS-CoV-2 Nucleocapsid protein  
23 at an average of 6 months post-infection compared to healthy COVID convalescents. Neuro-  
24 PASC patients also had enhanced virus-specific production of IL-6 from and diminished  
25 activation of CD8<sup>+</sup> T cells. Furthermore, the severity of cognitive deficits or quality of life  
26 disturbances in Neuro-PASC patients were associated with a reduced diversity of effector  
27 molecule expression in T cells but elevated IFN- $\gamma$  production to the C-terminal domain of  
28 Nucleocapsid protein. Proteomics analysis showed enhanced plasma immunoregulatory proteins  
29 and reduced pro-inflammatory and antiviral response proteins in Neuro-PASC patients compared  
30 with healthy COVID convalescents, which were also correlated with worse neurocognitive  
31 dysfunction. These data provide new insight into the pathogenesis of long COVID syndrome and  
32 a framework for the rational design of predictive biomarkers and therapeutic interventions.

33 **Keywords:** COVID-19 immunity, T cell memory, Neuro-PASC, long COVID,  
34 immunoregulation, proteomics

35 **Main Text**

36 **Introduction**

37 SARS-CoV-2 is the causative agent of a worldwide pandemic that was first identified in  
38 December, 2019. There have been more than 610 million cases and over 6 million deaths  
39 globally attributable to COVID-19 (1). Although highly effective vaccines are now used to  
40 prevent severe disease and death caused by SARS-CoV-2, long-term sequelae after infection  
41 have become an urgent medical concern.

42 SARS-CoV-2 infection can result in a wide spectrum of clinical manifestations ranging  
43 from asymptomatic infection to severe multi-organ dysfunction (2, 3), and predictive biomarkers  
44 to prognosticate either of these clinical outcomes are currently lacking. Globally, the estimated  
45 fatality rate following SARS-CoV-2 infection is approximately 2%, but not all patients recover  
46 to their baseline states (4). “Long COVID” affects an estimated 30% of people infected with  
47 SARS-CoV-2 and includes symptoms persisting more than 4 weeks after infection, termed “post-  
48 acute sequelae of SARS-CoV-2 infection” or PASC (5). According to the Centers for Disease  
49 Control and Prevention (CDC) and others, Neuro-PASC is clinically defined as new neurologic  
50 or neurocognitive symptoms persisting for more than 4 weeks after disease onset and is often not  
51 concomitant with diagnosis of acute infection (6, 7). Although the majority of people with  
52 SARS-CoV-2 infection experience mild disease not requiring hospitalization, more than half of  
53 these individuals have symptoms persisting more than 4 months after acute infection (8). This is  
54 similar to the frequency of neuropsychiatric symptoms reported by people infected Middle East  
55 Respiratory virus (MERS) and SARS-CoV-1 up to 3.5 years after acute infection (9), suggesting  
56 that SARS coronaviruses commonly cause long-term neurological sequelae. Similarly, recent

57 studies on recovered COVID-19 patients showed significant cognitive deficits in attention,  
58 working memory, and emotional processing months after the resolution of acute infection (10).

59 T cell immunity is necessary for the host defense against SARS-CoV-2. In particular,  
60 CD4<sup>+</sup> T cell responses directed against the Spike protein were found in 100% of COVID  
61 convalescents (11), and virus-specific T cell responses were sub-optimal or impaired in severely  
62 ill COVID patients (12). Autopsies of severe COVID patients found impaired germinal center  
63 formation linked to a defective T follicular helper cell response (13). Studies have also shown  
64 that CD8<sup>+</sup> T cell depletion after SARS-CoV-2 infection of rhesus macaques impairs anamnestic  
65 immune protection after subsequent re-infection (14). Moreover, memory T cell responses can be  
66 detected in patients exposed to the closely related SARS-CoV-1 up to 4 years after virus  
67 exposure (15). Despite these studies showing a role for T cells in protecting against acute SARS-  
68 CoV-2 infection, the impact of T cell responses on PASC remains poorly understood. Therefore,  
69 we sought to determine how SARS-CoV-2-specific T cell responses contribute to the etiology  
70 and pathogenesis of PASC.

71 Here, we focus on a group of Neuro-PASC patients who mostly had mild acute disease  
72 but subsequently developed a substantial reduction in their quality of life, psychiatric, and  
73 cognitive parameters. Our data show four critical findings linking T cell responses with Neuro-  
74 PASC symptoms. Firstly, we show that Neuro-PASC patients exhibit decreased Spike- but  
75 increased Nucleocapsid- and Membrane-specific T cell responses compared with healthy  
76 COVID convalescents without persistent symptoms. Secondly, CD8<sup>+</sup> memory T cells from  
77 Neuro-PASC patients produce substantially more IL-6 in response to Spike and Nucleocapsid  
78 peptides. Thirdly, the increased severity of cognitive deficits and decreased quality of life  
79 markers are positively correlated with IFN- $\gamma$  production in response to Nucleocapsid antigens

80 and altered effector molecule expression in memory T cells. Lastly, Neuro-PASC patients  
81 presented with higher levels of immunoregulatory proteins and lower levels of antiviral and T<sub>h</sub>1  
82 inflammatory proteins in proteomics analysis. Together, these data suggest wide-ranging  
83 immunological alterations in Neuro-PASC patients, with important implications for appropriate  
84 diagnostic, prevention, and treatment strategies.

## 85 **Results**

### 86 *Clinical characteristics of Neuro-PASC patients and control participants*

87 We enrolled a total of 168 participants, including 143 prior to SARS-CoV-2 vaccination  
88 and 25 participants post-vaccination recruited from the Neuro-COVID-19 outpatient clinic at  
89 Northwestern Memorial Hospital or from the surrounding Chicago area. These included 91  
90 Neuro-PASC patients (“NP”; confirmed RT-PCR+ or anti-SARS-CoV-2 Spike IgG+) meeting  
91 Infectious Disease Society of America clinical criteria for COVID-19 starting after February  
92 2020 and had neurologic symptoms lasting at least 6 weeks post-infection, as previously reported  
93 (16). Among those, 66 (80.6%) were never hospitalized for pneumonia or hypoxia and had mild  
94 disease. We additionally recruited 43 COVID convalescents without lasting symptoms (“CC”;  
95 RT-PCR+ or seropositive for anti- SARS-CoV-2 Spike RBD IgG); and 34 healthy controls who  
96 were RT-PCR- and seronegative for SARS-CoV-2 Spike-IgG (“HC”; study design in Fig. 1A).

97 Neuro-PASC patients displayed a constellation of neurological symptoms similar to those  
98 previously reported (17) such as headache, fatigue, brain fog, and myalgia (Fig. 1B). Results  
99 from the patient reported outcomes information system (PROMIS-57) survey (18) showed that  
100 Neuro-PASC patients scored significantly lower on physical function and higher on anxiety,  
101 depression, pain and other quality of life metrics compared with COVID convalescents or the  
102 national average (Fig. 1C). NIH toolbox tests administered to assess cognitive function (19) in  
103 Neuro-PASC patients also showed significantly lower T scores in the attention module,  
104 indicative of cognitive dysfunction relative to a demographic-matched population (Fig. 1D).

### 105 *Neuro-PASC T cell responses to SARS-CoV-2 structural proteins*

106 To determine the specificity of T cell responses to SARS-CoV-2 in Neuro-PASC and  
107 COVID convalescent groups, we performed cytokine ELISPOT. Bulk peripheral blood  
108 mononuclear cells (PBMC) from each subject were stimulated with overlapping peptides from  
109 the Spike (S), Nucleocapsid (N), or Membrane (M) structural proteins of SARS-CoV-2 (Fig. S1).  
110 IFN- $\gamma$ <sup>+</sup> and IL-2<sup>+</sup> T cell responses to S peptides were similar between Neuro-PASC patients and  
111 COVID convalescents (Fig. 2A left panel, S2A). However, Neuro-PASC patients exhibited  
112 higher IFN- $\gamma$ <sup>+</sup> T cell responses against N and M peptides (Fig. 2A, right panels) compared with  
113 COVID convalescents. Further experiments dividing Nucleocapsid peptides into 3 pools (Fig.  
114 2B) pinpointed the increased T cell reactivity in Neuro-PASC patients to the C-terminal region  
115 of the protein (Fig. 2C), particularly in amino acids 309-402 (Fig. 2D). T cell receptor (TCR  
116 sequencing) was then performed on a subset of study participants. The top N3 region-specific  
117 TCR clone was more highly expanded in Neuro-PASC patients than COVID convalescents (Fig.  
118 2E), consistent with IFN- $\gamma$  responses in Fig. 2C. Antibody titers against the Spike receptor-  
119 binding domain (RBD) did not differ between Neuro-PASC and COVID convalescent groups  
120 (Fig. 2F). No differences in antibody titers against the irrelevant Haemagglutinin protein from  
121 Influenza virus were found between groups (Fig. 2G), demonstrating immune responses were  
122 SARS-CoV-2-specific.

123 No significant differences were found in IL-2 and IL-17 cytokine responses between  
124 groups (Fig. S2B-F). Healthy controls exhibited some IL-2 production to N peptides likely  
125 caused by cross-reactivity with endemic coronaviruses (Fig. S2B) as suggested previously (20).  
126 Importantly, hospitalization prior to the development of Neuro-PASC did not affect the IFN- $\gamma$   
127 response to SARS-CoV-2 (Fig. S2G-H). Though post-hospitalized Neuro-PASC patients trended

128 towards lower IFN- $\gamma$ <sup>+</sup> T cell responses compared with non-hospitalized patients, these were  
129 statistically non-significant.

### 130 *Virus-specific activation of CD4<sup>+</sup> Tfh cells in Neuro-PASC*

131 Comparison of CD4<sup>+</sup> T cell subsets from hospitalized and non-hospitalized COVID  
132 patients showed that severe disease was associated with elevated T follicular helper (Tfh)  
133 proportions relative to patients with mild disease (21). We thus determined whether Tfh  
134 activation (see gating scheme in Fig. S3C) could similarly differentiate Neuro-PASC patients  
135 from COVID convalescents. Immunophenotyping showed no differences between groups in total  
136 percentages of most T cell subsets, including Tfh cells, in the unstimulated condition (Fig. S4).  
137 Therefore, we conducted functional assays to determine T cell reactivity. The activation-induced  
138 marker (AIM) assay measures cytokine-independent, antigen-specific, TCR-mediated T cell  
139 activation and has been previously used to detect SARS-CoV-2-specific CD4<sup>+</sup> (CD137<sup>+</sup>CD134<sup>+</sup>)  
140 and CD8<sup>+</sup> (CD69<sup>+</sup>CD137<sup>+</sup>) T cells (11). We used this method to investigate Tfh activation. N-  
141 specific CD134<sup>+</sup>CD137<sup>+</sup> (AIM<sup>+</sup>) Tfh cells were significantly elevated in Neuro-PASC patients  
142 compared with COVID convalescents, while the opposite pattern was observed for S and M-  
143 specific Tfh cells (Fig. 3A-B). Consistent with these results, N-specific IgG titers were  
144 significantly elevated in Neuro-PASC patients (Fig. 3C). Neither N-specific Tfh cell activation  
145 nor anti-N antibody responses decreased with the time post-acute infection in Neuro-PASC  
146 patients (Fig. S5A-B).

### 147 *CD4<sup>+</sup> T cell effector functions differ in Neuro-PASC patients vs. COVID convalescents*

148 To probe the effector functions of virus-specific CD4<sup>+</sup> T cells, we determined whether  
149 Neuro-PASC patients and COVID convalescents had altered patterns of cytokine production in



150 response to viral antigens. We focused on T cell responses to N and S2 peptide pools because  
151 these antigens provoked maximal differences between Neuro-PASC patients and control groups.  
152 CD4<sup>+</sup> T cells from Neuro-PASC patients expressed lower levels of IL-6 and TNF- $\alpha$  relative to  
153 COVID convalescents following stimulation with N peptides (Fig. 3D-E), and higher levels of  
154 TNF- $\alpha$  after S peptide stimulation (Fig. S6). No differences were observed in the unstimulated  
155 condition (Fig. S5C). CD4<sup>+</sup> T cells can also produce cytolytic granules that help eliminate virus-  
156 infected cells (22) as in Influenza or HIV infection (23, 24). However, enhanced production of  
157 cytolytic granules from CD4<sup>+</sup> T cells was also associated with disease severity in acutely  
158 infected COVID-19 patients (25). We therefore investigated cytolytic granule (granzyme A, B,  
159 M, and Perforin), IL-6, and TNF- $\alpha$  expression in CD4<sup>+</sup> T cells following stimulation with SARS-  
160 CoV-2 peptides. Neuro-PASC patients had significant elevations in dual and triple cytokine- and  
161 cytolytic granule-producing CD4<sup>+</sup> T cells after S pool stimulation, including in granzyme A/B<sup>+</sup>,  
162 TNF- $\alpha$ /IL-6<sup>+</sup>, and granzyme A/B-Perforin<sup>+</sup> CD4<sup>+</sup> T cells (Fig. 3F). S-specific CD4<sup>+</sup> T cells from  
163 Neuro-PASC patients also retained polyfunctionality similar to healthy controls, while CD4<sup>+</sup> T  
164 cells from COVID convalescents were limited to producing mostly granzymes (category 2 in  
165 yellow, Fig. 3G-H; unstimulated and N pool stimulation in Fig. S7A-B). These data suggest that  
166 cytotoxic responses to Spike protein in CD4<sup>+</sup> T cells from Neuro-PASC patients are functionally  
167 distinct from those in COVID convalescents, and do not significantly differ from unexposed  
168 healthy controls.

### 169 *Attenuated CD8<sup>+</sup> memory T cell activation in Neuro-PASC patients*

170 CD8<sup>+</sup> memory T cells are important for effective anti-viral immunity and can persist for  
171 several years after the related SARS-CoV-1 infection (26). However, little is known about  
172 memory CD8<sup>+</sup> T cell function in Neuro-PASC. CD8<sup>+</sup> T effector memory cells (TEM or

173 TEMRA; gating strategy in Fig. S3A) are poised for rapid cytotoxic function upon antigen re-  
174 encounter. CD8<sup>+</sup> TEM exhibited significant antigen-driven activation in COVID convalescents  
175 but not in Neuro-PASC patients (Fig. 4A-B). Total percentages of CD8<sup>+</sup> TEMRA cells were also  
176 significantly elevated in Neuro PASC patients (Fig. 4C), but despite their increased numbers,  
177 these cells were less activated by S and N peptides compared with COVID convalescents (Fig.  
178 4D-E). Similarly, virus-specific cytokine production differed in CD8<sup>+</sup> T cell subsets between  
179 groups. S and N peptides provoked elevated IL-6 production on a per-cell basis in CD8<sup>+</sup> TEM  
180 from Neuro-PASC patients compared to COVID convalescents (Fig. 4F-G), as determined by  
181 mean fluorescence intensity (MFI). Monocytes and neutrophils, innate immune cells that are  
182 among the main producers of IL-6 (27), also expressed significantly more IL-6 after stimulation  
183 with viral peptides in Neuro-PASC patients compared to control groups (Fig. S8A-B), possibly  
184 due to enhanced innate receptor stimulation (28, 29).

185         Additionally, CD8<sup>+</sup> T cells had differing patterns of cytolytic effector molecule  
186 production between groups. CD8<sup>+</sup> TEM from Neuro-PASC patients exhibited elevated S-specific  
187 granzyme production compared with COVID convalescents or healthy controls (Fig. 4H;  
188 unstimulated and N pool stimulation in Fig. S7C-D). However, S peptides did not significantly  
189 alter CD8<sup>+</sup> TEMRA effector functions in Neuro-PASC patients relative to unexposed healthy  
190 controls. In contrast, COVID convalescents produced more cytolytic granzymes and Perforin,  
191 and this functional change was consistent with the higher activation seen in Fig. 4E (Fig. 4I;  
192 unstimulated and N pool stimulation in Fig. S7E-F). Expression of the inhibitory receptor PD-1  
193 did not differ in CD8<sup>+</sup> TEM after stimulation with viral peptides in Neuro-PASC patients and  
194 COVID convalescents (Fig. S8C).

195 *Impaired cognition and decreased quality of life metrics correlate with distinct patterns of virus-*  
196 *specific T cell responses*

197         We next probed whether within-group differences in adaptive immune responses  
198 correlated with clinical measures of symptom severity in Neuro-PASC. Poorer cognitive and  
199 anxiety scores were correlated with elevated IFN- $\gamma$ -expressing T cells directed against the C-  
200 terminal domain of N protein (Fig. 5A). Spearman rank correlation analysis further demonstrated  
201 negative correlations between attention and executive function scores and IFN- $\gamma$  responses to the  
202 C-terminal domain of N protein as well as RBD-specific antibody responses (Fig. 5B), among  
203 other parameters. To determine associations between clinical scores and T cell effector functions,  
204 we separated T scores from NIH Toolbox or PROMIS-57 measurements (Fig. 1C-D) into  
205 quartiles and used only the lowest and highest groups (Q1 vs. Q4) for analysis (Fig. S9A, red  
206 boxes). Neuro-PASC subjects reporting high degrees of pain produced significantly more IL-6  
207 and less cytotoxic effector molecules from CD8<sup>+</sup> T cells than those with low pain scores (Fig.  
208 5C-D). Further, patients with low depression scores had virus-specific CD8<sup>+</sup> TEM that expressed  
209 higher levels of perforin, while those reporting high scores had elevated granzyme production  
210 (Fig. 5E, F). Cognitive impairment was also significantly correlated with T cell responses.  
211 Patients scoring low on attention by NIH Toolbox had CD8<sup>+</sup> T central memory cells (TCM)  
212 expressing different patterns of cytolytic effectors compared to those with high attention scores  
213 (Fig. 5G-H). Similar analyses were performed for other memory T cell subsets, and significant  
214 differences were also found in correlations with processing speed, working memory, and global  
215 pain (Fig. S9B-K).

216 *Elevated immunoregulatory proteins and decreased antiviral and T<sub>H</sub>1- response proteins in*  
217 *Neuro-PASC patients correlate with cognitive dysfunction*

218 The multiplexed proteomics platform SOMAscan has been successfully used in previous studies  
219 to identify biomarkers associated with conditions such as hepatocellular carcinoma (30),  
220 Alzheimer's disease (31), and drug treatment of myocardial infarction (32). The technology  
221 utilizes the natural 3D folding of single-stranded DNA-based protein recognition aptamers to  
222 quantify levels of more than 7000 unique proteins in biological fluids (33). We used this  
223 platform to determine whether Neuro-PASC patients had proteomic signatures distinct from  
224 COVID convalescents through pathway analysis as well as comparison of individual protein  
225 levels. Gene set enrichment pathway analysis (GSEA) has previously been used on proteomics  
226 data to identify dysregulated circuits in Duchenne muscular dystrophy (34). GSEA similarly  
227 identified an enrichment in immunoregulatory pathway proteins in Neuro-PASC patients and  
228 conversely, elevated antiviral and T<sub>h</sub>1-type immune pathways in COVID convalescents (Fig.  
229 6A). Comparison of individual proteins enriched in the immunoregulatory pathway identified  
230 significantly elevated CD247, SIGLEC7, MICA, and other molecules involved in regulating T  
231 cell activation (Fig. 6B, top panel). In contrast, plasma from healthy COVID convalescents were  
232 enriched in the antiviral TASOR pathway proteins H2AC11, METTL3, and MAP4K1 (Fig. 6B,  
233 bottom panel), among others, which are involved in preventing intracellular viral replication and  
234 T cell differentiation (35). A number of proteins were correlated with cognitive performance or  
235 neurologic symptom severity in both pathways (Fig. 6C), with a particularly significant negative  
236 correlation between self-reported cognition scores and expression of the inhibitory NK cell/CD8<sup>+</sup>  
237 T cell receptor KLRC1 (Fig. 6C, left panel).

238 Overall, our study demonstrates that Neuro-PASC patients have elevated IFN- $\gamma$  responses  
239 to internal (Nucleocapsid & Membrane) proteins of SARS-CoV-2, enhanced activation of Tfh  
240 cells linked to increased anti-Nucleocapsid antibody production, but impaired activation of CD8<sup>+</sup>

241 memory T cells compared with COVID convalescents. In addition, we show unique correlations  
242 between the severity of cognitive deficits or quality of life impairments and increased virus-  
243 specific T cell responses, suggesting that higher T cell responses are not always linked to better  
244 clinical outcomes. Importantly, proteomics analysis found upregulations in immunoregulatory  
245 pathway proteins and downregulation in inflammatory and antiviral response proteins in Neuro-  
246 PASC patients that were highly correlated with neurocognitive dysfunction. Together, we show  
247 that Neuro-PASC patients exhibit distinct activation and effector signatures in multiple aspects  
248 of the T cell response.

249 **Discussion**

250 COVID-19 is recognized as a multi-organ disease with long-term sequelae associated  
251 with neurological dysfunction. PASC has been reported in up to 87% of those hospitalized with  
252 SARS-CoV-2 pneumonia and in 30% of those with mild disease who do not require  
253 hospitalization (36, 37). Long-term sequelae after coronavirus infections can persist for years (9);  
254 therefore, it is important to characterize immune responses associated with PASC. Prior studies  
255 have focused on acute infection in COVID convalescents broadly as opposed to focusing on  
256 those with PASC (38, 39). We aimed to fill this knowledge gap and examine how virus-specific  
257 adaptive immunity differs in patients with Neuro-PASC vs. healthy COVID convalescents.

258 Clinically, Neuro-PASC resembles myalgic encephalomyelitis/chronic fatigue syndrome  
259 (ME/CFS), which is often reported as a post-viral syndrome (40). The causes of ME/CFS remain  
260 elusive, and the underlying mechanisms of Neuro-PASC are similarly unknown. One hypothesis  
261 is that Neuro-PASC symptoms may be caused by direct infection of the CNS. SARS-CoV-2 may  
262 gain entry into the CNS through the olfactory bulb and has been shown to infect neurons in vitro,  
263 which is supported by viral protein expression in neurons from post-mortem autopsies and  
264 presence of virus in the brain in mouse models (41, 42). However, other studies were unable to  
265 find evidence of SARS-CoV-2 in the CNS of patients who died with neurologic symptoms (43)  
266 or in the cerebrospinal fluid (CSF) (44), suggesting that infection of the nervous system may be  
267 transient or may not occur in all infected individuals. Importantly, a study in Neuro-PASC  
268 patients did not find any SARS-CoV-2 RNA or intrathecally-produced viral antibodies in the  
269 CSF at 90 days post-infection (45). As lumbar punctures or brain biopsies are not indicated in the  
270 majority of Neuro-PASC patients seen in our clinic, reproducing the above study results in  
271 ambulatory populations is not possible. Additional hypotheses for Neuro-PASC pathogenesis

272 include autoimmune mechanisms which are suggested by the increased ratio of females to males  
273 affected, similar to that seen in rheumatoid arthritis or other autoimmune diseases (16, 46), or the  
274 possibility of persistent SARS-CoV-2 infection (47). It is also important to mention that the  
275 majority of Neuro-PASC patients in our study had one or more comorbidities, while comorbidity  
276 rates in COVID convalescents were lower (Figure 1B). It is thus possible that the presence of  
277 comorbidities can increase the predilection for Neuro-PASC, and this combined with the  
278 heterogeneous severity of acute COVID-19 in these patients may bias our results compared with  
279 healthy COVID convalescents. However, more than half of U.S. adults are estimated to have one  
280 or more chronic health conditions (48), which may put millions of people at risk for long COVID  
281 syndrome.

282 T cell responses were similar between Neuro-PASC and COVID convalescent groups in  
283 response to SARS-CoV-2 S peptides (Fig. 2A, S2A). These results are expected as T cell  
284 responses to Spike protein remain diverse after both infection (11) and vaccination (49). In  
285 contrast, T cells from Neuro-PASC patients retained high IFN- $\gamma$  responses to N and M peptides,  
286 while COVID convalescents had limited reactivity to the C-terminal domain of N protein (Fig.  
287 2C). Further characterization localized the enhanced Neuro-PASC T cell reactivity to amino  
288 acids 309-402 of N protein (Fig. 2D). It is possible that Neuro-PASC T cell responses remain  
289 high towards N and M protein due to altered T cell clonal expansion patterns compared with  
290 COVID convalescents. Studies have identified SARS-CoV-2 specific T cell receptor (TCR)  
291 sequences that are clonally expanded in a large population of COVID convalescents (50).  
292 However, these studies did not determine whether convalescent subjects had PASC at the time of  
293 sample collection. Further studies are needed to determine whether the enhanced T cell responses

294 to N and M proteins in Neuro-PASC patients correspond to differential patterns of virus-specific  
295 TCR clonal expansion which may inform vaccination and treatment strategies.

296 T follicular helper (Tfh) cells can be important for the elicitation of antibody responses  
297 after SARS-CoV-2 infection by helping to establish germinal centers in secondary lymphoid  
298 organs, ultimately resulting in the production of high-affinity antibodies (51). SARS-CoV-2 N  
299 peptides activated Tfh cells in Neuro-PASC but not COVID convalescent groups (Fig. 3A-B),  
300 while the opposite pattern was observed in response to S and M peptides. Tfh responses are also  
301 dependent on antigen levels and directly correlate with the magnitude of the antibody response  
302 (52). Indeed, Neuro-PASC patients with high N-specific Tfh activation also displayed elevated  
303 antibody titers compared to controls (Fig. 3C). This was despite the fact that we obtained their  
304 samples more than 6 months after acute infection when anti-N antibody titers would fall beyond  
305 detection in most COVID convalescents (53).

306 Effective generation of T cell memory responses can be important to protect against  
307 future infections with the same pathogen. CD8<sup>+</sup> T effector memory (TEM) cells from Neuro-  
308 PASC patients displayed reduced antigen-specific activation compared with COVID  
309 convalescents (Fig. 4A-B), suggestive of a diminished effector response. CD137 may play a role  
310 here as costimulation provides an important signal necessary for the activation of virus-specific  
311 T cells (54), but this costimulatory marker was reduced on CD8<sup>+</sup> memory T cells from Neuro-  
312 PASC patients relative to COVID convalescents (Fig. 4A-4B). Prior studies have shown that  
313 asymptomatic individuals display a robust T cell response to SARS-CoV-2 Nucleocapsid protein  
314 after infection (39), suggesting that the lack of T cell memory responses in Neuro-PASC patients  
315 is detrimental.



316 We also observed a significant elevation in CD8<sup>+</sup> TEMRA cells in Neuro-PASC patients  
317 compared to control groups (Fig. 4C). CD8<sup>+</sup> TEMRA cells have been shown to accumulate  
318 during persistent viral infections and contribute to immunosenescence (55). Their decreased  
319 virus-specific activation in Neuro-PASC patients (Fig. 4E) suggests lower cytotoxic capacity  
320 compared with healthy COVID convalescents and coincides with their elevated production of  
321 granzyme in Fig. 4I. Our data suggest that CD8<sup>+</sup> TEMRA cells may be functionally anergic in  
322 Neuro-PASC patients compared with COVID convalescents and may contribute to the  
323 pathogenesis of PASC.

324 Significantly, CD8<sup>+</sup> TEM from Neuro-PASC patients expressed higher levels of IL-6 in  
325 response to viral peptides, while in contrast CD4<sup>+</sup> T cells from COVID convalescents expressed  
326 higher IL-6 (Fig. 4F-G, 3E). Clinically, CD8<sup>+</sup> T cell production of IL-6 was also significantly  
327 correlated patient-reported pain scores (Fig. 5C). IL-6 plays opposing regulatory roles in T cell  
328 memory responses during viral infections. CD4<sup>+</sup> memory T cells require IL-6 for activation and  
329 proliferation during viral infection (56). Thus, it is possible that elevated IL-6 production by  
330 CD4<sup>+</sup> T cells in COVID convalescents is a correlate of protective anti-viral immunity. However,  
331 IL-6 can also suppress T<sub>H</sub>1 differentiation (57) and was found to promote pathogen survival  
332 while exacerbating clinical disease during SARS-CoV-1 infection (58). In fact, blocking IL-6  
333 activity enhances virus-specific CD8<sup>+</sup> T cell immunity (59), and overexpression of IL-6 can lead  
334 to viral persistence by impairing CD8<sup>+</sup> lytic functions (60) and the development of CD8<sup>+</sup> T cell  
335 memory (61). Indeed, severely ill COVID-19 patients had high serum levels of IL-6 that  
336 significantly correlated with poor clinical outcomes (38). Thus, our data suggest that enhanced  
337 IL-6 production by CD8<sup>+</sup> T cells and/or innate immune cells (Fig. S8A-B) may be involved in

338 the etiology or pathogenesis of Neuro-PASC and reveal new avenues of research for the  
339 treatment of long COVID through limiting IL-6 activity.

340 Neuro-PASC patients reported significantly elevated levels of anxiety, depression, pain,  
341 and other symptoms compared with COVID convalescents (Fig. 1C). The severity of these  
342 deficits was correlated with Ag-specific enhancements in polyfunctionality but decreases in  
343 polarization of memory T cell subsets (Fig. 5, S9). It is possible that T cell activation contributes  
344 to some of these symptoms. Studies in rodents have shown that T cell activation can affect the  
345 severity of pain and analgesia (62); it may follow that aberrant T cell activation can be linked to  
346 high pain scores. Inflammation-related transcriptional programs are also differentially regulated  
347 in T cells from patients with depression (63), providing a possible link between enhanced  
348 granzyme production and elevated depression scores (Fig. 5E, S9B). T cell-derived cytokines  
349 can also impact learning and memory. Mouse models of West Nile and Zika viral encephalitis  
350 have demonstrated that IFN- $\gamma$  production from CD8<sup>+</sup> T cells in the brain is responsible for  
351 neuronal apoptosis and spatial learning deficits (64). The association of SARS-CoV-2-specific  
352 cytokine signatures with the severity of cognitive and quality of life deficits in Neuro-PASC  
353 patients may therefore provide some predictive value in terms of clinical outcomes.

354 Proteomic analysis of patient plasma demonstrated that Neuro-PASC patients had  
355 relatively blunted levels of pro-inflammatory and antiviral response-associated proteins  
356 compared to COVID convalescents, while simultaneously having elevated immunoregulatory  
357 protein expression (Fig. 6A). Further analyses at the individual protein level showed  
358 upregulation of immunoregulatory proteins such as CD33 and NCR1 in Neuro-PASC plasma,  
359 involved in T cell immunosuppression in acute myeloid leukemia (65) and suppression of  
360 antiviral CD8<sup>+</sup> T cell responses (66), respectively. These data support our findings showing

361 decreased antiviral CD8<sup>+</sup> TEM and TEMRA responses (Fig. 4) and suggest that an imbalance  
362 between immunoregulatory and antiviral pathways may play a role in Neuro-PASC  
363 pathogenesis. In line with this, one of the strongest associations we found with poor cognitive  
364 scores involved the NK and CD8<sup>+</sup> T cell inhibitory receptor KLRC1 that downregulates  
365 cytotoxic capacity (67) (Fig. 6C). KLRC1 expression on CD8<sup>+</sup> T cells is upregulated by IL-6  
366 (68), and enhanced KLRC1 expression has been found on exhausted CD8<sup>+</sup> T cells from acute  
367 COVID-19 patients (69). Based on our data, it is therefore possible that enhanced IL-6  
368 production from CD8<sup>+</sup> T cells in Neuro-PASC patients may upregulate KLRC1 and suppress  
369 CD8<sup>+</sup> T cell function, which may impact Neuro-PASC symptom severity. Together, these data  
370 illuminate a specific T cell signature associated with of Neuro-PASC.

### 371 **Limitations of study**

372 One limitation is the relatively small sample size of unvaccinated COVID convalescent  
373 subjects. This was due to the wide implementation of SARS-CoV-2 vaccines in Chicago area  
374 soon after beginning study enrollment. Another limitation was not being able to control for time  
375 of sample collection with respect to date of COVID-19 symptom onset. Additionally, as we  
376 hypothesize that Neuro-PASC could be the result of a persistent or protracted infection, future  
377 studies would require testing of potential cryptic reservoirs, including stool or CNS tissue from  
378 Neuro-PASC patients.

379 **Methods**

380 *Study design*

381 We attempted to include a robust sample size for every patient group, including those in the  
382 vaccine portion of the study. Enrollment sizes for the COVID convalescent group in particular  
383 was limited despite posting recruitment flyers as well as on social media due to the widespread  
384 rollout of vaccines. Data collection was stopped in our study at the indicated endpoints. Data  
385 inclusion/exclusion criteria are described below in the *Study participants* section. Endpoints were  
386 selected prospectively. Replicates for each experiment are described in figure legends.

387       Research objectives were to identify and characterize T cell responses to SARS-CoV-2  
388 linked to Neuro-PASC pathogenesis and specify how these responses differed from COVID  
389 convalescents without lasting symptoms. We enrolled Neuro-PASC outpatients, COVID  
390 convalescents, and unexposed healthy controls for our study. Experimental design is outlined in  
391 Fig. 1A. Subjects were not randomized and investigators were not blinded to the study subjects'  
392 grouping prior to conducting experiments and analyzing data.

393 *Study participants, NIH Toolbox, and PROMIS-57 data collection*

394 We enrolled consenting adult outpatients seen in the Neuro-PASC-19 clinic at Northwestern  
395 Memorial Hospital from September 2020-September 2021, including 89 Neuro-PASC patients  
396 with documented PCR+ or seropositive IgG results for SARS-CoV-2. In parallel, we recruited 43  
397 COVID convalescents from the surrounding community who tested either PCR+ or seropositive  
398 for SARS-CoV-2 before vaccination but had no lingering neurological symptoms and 34 healthy  
399 controls who tested PCR- for SARS-CoV-2 and were also seronegative for IgG against SARS-  
400 CoV-2 Spike RBD prior to vaccination. All study subjects remained living throughout the period

401 of observation. Heparinized blood samples were collected one time from each subject at an  
402 average of 161.5-223.0 days post-symptom onset (as in Fig. 1B). Other demographic  
403 information, including comorbidity information, is contained in Fig. 1B and Supplementary  
404 Tables 2-6. Neuro-PASC patients completed a cognitive function evaluation in the clinic  
405 coincident or near the date of their blood sample acquisition with the National Institutes of  
406 Health (NIH) Toolbox v2.1 instrument, including assessments of: processing speed (pattern  
407 comparison processing speed test); attention and executive memory (inhibitory control and  
408 attention test); executive function (dimensional change card sort test); and working memory (list  
409 sorting working memory test) (19). PROMIS-57 patient-reported quality of life assessments were  
410 administered to Neuro-PASC and COVID convalescent subjects an average of 72 days post-  
411 sample collection. Both PROMIS-57 and NIH Toolbox results are expressed as T-scores with a  
412 score of 50 representing the normative mean/median of the US reference population and a  
413 standard deviation of 10. Toolbox results are adjusted for age, education, gender, and  
414 race/ethnicity. Lower cognition T-scores indicate worse performance while higher fatigue,  
415 depression, anxiety, or pain interference T-scores indicate greater symptom severity.

#### 416 *PBMC and plasma collection*

417 30mL of venous blood from study volunteers was collected in blood collection tubes containing  
418 sodium heparin from BD Biosciences. Whole blood was layered on top of 15mL of Histopaque  
419 1077 (Sigma-Aldrich) in 50mL Leucosep blood separation tubes (Greiner Bio-One) and spun at  
420 1000g for 18min at RT. Plasma was collected and stored at -80°C. The PBMC layer was  
421 collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality  
422 Biologicals). PBMCs were used in assays either immediately or frozen down for use in the near  
423 term.

424 *SARS-CoV-2 peptide antigens*

425 All S, N and M peptide arrays used in ELISPOT and flow cytometry studies were obtained from  
426 BEI Resources, NIAID, NIH: Peptide Array, SARS-Related Coronavirus 2 Spike (S) Protein;  
427 NR-52402, Nucleocapsid (N) Protein, NR-52404; Membrane (M) Protein, NR-52403. The S  
428 peptide array consisted of 181 peptides of 13-17aa in length and split into 6 sub-pools (S1-S6)  
429 containing 30-31 peptides each. The N peptide array consisted of 59 peptides of 13-17aa each  
430 split into 3 sub-pools containing 29-30 peptides each (Fig. 2B) or with 1 sub-pool further divided  
431 into 5 pools of 3-4 peptides each (Fig. 2D). The M peptide array consisted of 31 peptides of 12-  
432 17aa; details in Fig. S1. All peptides were dissolved in either sterile H<sub>2</sub>O or 50% sterile H<sub>2</sub>O-  
433 DMSO up to 1mL for a universal 1mg/mL stock concentration. Peptides were used at a final  
434 concentration at 2µg/mL in all assays.

435 *IgG Spike RBD and Nucleocapsid ELISA*

436 Antigen-specific total antibody titers were measured by ELISA as described previously(70). In  
437 brief, 96-well flat-bottom MaxiSorp plates (Thermo Scientific) were coated with 1 µg/ml of  
438 Spike RBD for 48 hr at 4°C. Plates were washed three times with wash buffer (PBS + 0.05%  
439 Tween 20). Blocking was performed with blocking solution (PBS + 0.05% Tween 20 + 2%  
440 bovine serum albumin), for 4 hr at room temperature. 6 µl of sera was added to 144 µl of  
441 blocking solution in the first column of the plate, 1:3 serial dilutions were performed until row  
442 12 for each sample, and plates were incubated for 60 min at room temperature. Plates were  
443 washed three times with wash buffer followed by addition of secondary antibody conjugated to  
444 horseradish peroxidase, goat anti-human IgG (H + L) (Jackson ImmunoResearch) diluted in  
445 blocking solution (1:1000) and 100 µl/well was added and incubated for 60 min at room  
446 temperature. After washing plates three times with wash buffer, 100 µl/well of Sure Blue

447 substrate (SeraCare) was added for 1 min. Reaction was stopped using 100  $\mu$ l/well of KPL TMB  
448 Stop Solution (SeraCare). Absorbance was measured at 450 nm using a Spectramax Plus 384  
449 (Molecular Devices). SARS-CoV-2 RBD and N proteins used for ELISA were produced at the  
450 Northwestern Recombinant Protein Production Core by Dr. Sergii Pshenychnyi using plasmids  
451 that were produced under HHSN272201400008C and obtained from BEI Resources, NIAID,  
452 NIH: Vector pCAGGS containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike  
453 glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding domain (RBD), NR-  
454 52309, nucleocapsid gene NR-53507.

#### 455 *Cell stimulation and IFN- $\gamma$ /IL-2 ELISPOT*

456 Multiscreen-IP plates (Millipore-Sigma) were coated overnight at 4°C with 2 $\mu$ g/mL anti-IFN- $\gamma$   
457 (clone 1-D1K, Mabtech) or 5 $\mu$ g/mL anti-IL-2 (clone MT2A91/2C95, Mabtech), washed with  
458 sterile PBS, and blocked with complete RPMI-10% FBS. PBMC isolated from Neuro-PASC,  
459 COVID convalescent, and healthy control subjects were used either freshly isolated or after  
460 thawing and resting overnight in media containing 10ng/ $\mu$ L recombinant human IL-15  
461 (Peprotech) at 37°C, 5% CO<sub>2</sub>. Cells were then plated at a concentration of 2.5x10<sup>5</sup> cells/well in  
462 100 $\mu$ L of media and stimulated with the indicated antigen mixtures from SARS-CoV-2 at a  
463 concentration of 2 $\mu$ g/mL in complete RPMI medium containing 5% human AB serum (Sigma-  
464 Aldrich) and 5ng/mL IL-15. Plates were incubated at 37°C, 5% CO<sub>2</sub> for 20h and washed 5x with  
465 dH<sub>2</sub>O and PBS-0.05% Tween-20 (PBS-T). 2 $\mu$ g/mL biotinylated IFN- $\gamma$  (clone 7-B6-1, Mabtech)  
466 or 5 $\mu$ g/mL IL-2 (clone MT8G10, Mabtech) diluted in PBS-10% FBS (PBS-F) was added to the  
467 respective wells and plates were incubated for 1.5h at RT. Plates were subsequently incubated  
468 for 40 minutes at RT in streptavidin-alkaline phosphatase in PBS-F (Jackson ImmunoResearch)  
469 was added after washing plates 5x in PBS-T. ELISPOT plates were developed using an Alkaline

470 Phosphatase Conjugate Substrate Kit according to manufacturer's instructions (Bio-Rad  
471 Laboratories, Carlsbad, CA). IFN- $\gamma$  or IL-2-producing cells were quantified using an  
472 ImmunoSpot reader (Cellular Technologies, Ltd., Shaker Heights, OH).

473

#### 474 *T cell receptor variable beta chain sequencing*

475 Immunosequencing of the CDR3, V, and J regions of human TCR $\beta$  chains was performed using  
476 the immunoSEQ<sup>®</sup> and T-MAP COVID Assays (Adaptive Biotechnologies, Seattle, WA).

477 Genomic DNA extracted from individual subject's PBMC was amplified in a bias-controlled  
478 multiplex PCR, followed by high-throughput sequencing. Sequences were then filtered to  
479 identify and quantitate the absolute abundance of each unique TCR $\beta$  template for further analysis  
480 as previously described (49). TCR specificities to SARS-CoV-2 Nucleocapsid were determined  
481 using immuneCODE, a publicly available database accessed via the immunoSEQ Analyzer  
482 platform. Peptide antigens specific for each TCR were then aligned to the Nucleocapsid amino  
483 acid sequence to demarcate regional specificity ("N1" vs. "N2" vs. "N3"). The value for the top  
484 expanded N3-specific TCR clone was counted for each NP and CC subject and analyzed in Fig.  
485 2E.

486

#### 487 *Antibodies and Flow Cytometry*

488 Fresh or frozen PBMCs isolated from the indicated patient groups were stimulated with antigen  
489 mixtures as above for 20-22h at 37°C, 5% CO<sub>2</sub>. For intracellular staining and cytokine detection,  
490 the Brefeldin-A Golgi plug (Biolegend) was added at a 1:1000 concentration 2 hours after  
491 antigenic stimulation commenced. Cells were washed with PBS-1% BSA after incubation and  
492 incubated with the indicated antibodies for surface phenotyping by AIM assay or for intracellular



493 cytokine staining (ICS; antibodies used described in Supplemental Table 1). Cells from each  
494 subject were left unstimulated in medium containing 5ng/mL IL-15 (“background”) or  
495 stimulated in the presence of the indicated antigens. Fixation and permeabilization was  
496 performed using Cytofix/Cytoperm (BD Biosciences). Surface staining was done in the dark at  
497 4°C for 30 minutes, while ICS was done in the dark at RT for 45 minutes. Flow cytometry was  
498 conducted on 2-5x10<sup>5</sup> cells per condition. Data was acquired on a BD FACSymphony Spectral  
499 analyzer and analyzed using FlowJo v10 (BD Biosciences) and SPICE-Pestle(71).

#### 500 *SOMAscan Profiling*

501 Heparinized plasma from 48 Neuro-PASC patients and 20 healthy COVID convalescents whose  
502 T cell and antibody responses were characterized in this study were assayed for the presence of  
503 more than 7,000 proteins using the SOMAscan proteomics platform. The SOMAscan assay is a  
504 sensitive, high-throughput technique that uses chemically modified DNA aptamers to  
505 specifically bind and quantify proteins of interest from very small quantities of plasma (33). The  
506 assay measures a wide range of receptors, intracellular signaling proteins, growth factors, and  
507 secreted proteins. All plasma samples were analyzed at SomaLogic Operating Co, Inc. (Boulder,  
508 CO).

#### 509 *SomaSCAN proteomics statistical analysis*

510 For statistical comparison, all relative fluorescence unit (RFU) values for individual proteins  
511 were first analyzed by Gene Set Enrichment Analysis (GSEA version 4.2.3; Broad Institute;  
512 Molecular Signatures Database: hallmark, curated, KEGG, and reactome gene sets) to determine  
513 significantly enriched pathways between NP and CC groups (Fig. 6A). The false discovery rate  
514 cutoff was 0.05. RFUs for proteins belonging to a particular pathway (immunoregulatory or

515 TASOR antiviral) that were enriched in NP or CC were then analyzed using two-tailed t-Test  
516 (Fig. 6B). Within-group correlations for Neuro-PASC symptoms with individual protein  
517 concentrations were determined using Spearman's correlation (Fig. 6C).

### 518 *Quantification and Statistical Analysis*

519 Statistical tests to determine significance are described in figure legends and conducted largely in  
520 Prism (GraphPad). SPICE is a data-mining software application that analyzes large FLOWJO  
521 data sets from polychromatic flow cytometry and organizes the normalized data graphically.  
522 SPICE defines a statistic for the nonparametric comparison of complex distributions based on  
523 multi-component measurements (71). For pie graphs or heatmaps generated using SPICE  
524 software analysis, statistics were determined by Permutation test following unstimulated  
525 background subtraction, with additional thresholding of 0.03% to account for noise, using  
526 SPICE-Pestle. *P*-values lower than 0.05 were considered statistically significant. Quartile  
527 stratification was performed within group for the Neuro-PASC cohort (Fig. S9A). Clinical data  
528 were collected and managed using REDCap electronic data capture tools hosted at Northwestern  
529 University Feinberg School of Medicine. All error bars on figures represent values  $\pm$  SEM.

### 530 *Study approval*

531 This study was approved by the Northwestern University Institutional Review Board (Koralnik  
532 Lab, IRB STU00212583). Informed consent was obtained from all enrolled participants. Samples  
533 were de-identified before banking.

### 534 **Data Availability**

535 The full datasets generated in the current study are available from the corresponding author upon  
536 requests.

537 **Acknowledgements**

538 We would like to thank Adaptive Biotechnologies for providing sequencing services and  
539 bioinformatics support, as well as the Flow Cytometry Core Facility at the Robert H. Lurie  
540 Comprehensive Cancer Center at Northwestern University supported by Cancer Center Support  
541 Grant (NCI CA060553) for their assistance in optimizing antibody panels and help with flow  
542 cytometry instrumentation. L.V. was supported by a T32 grant (NIAMS, T32AR007611) from  
543 the Department of Rheumatology, Northwestern University Feinberg School of Medicine.  
544 P.P.M. is supported by grants from the National Institute on Drug Abuse (NIDA,  
545 DP2DA051912) and from the National Institute of Biomedical Imaging and Bioengineering  
546 (NIBIB, U54EB027049).

547 **Author Contributions**

548 Conceptualization L.V. P.P.M. and I.K.; Investigation L.V., B.H., Z.O., P.H.L, N.P. and G.T.;  
549 Formal Analysis L.V., B.H., M.J., E.M.L., P.P.M. and N.P.; Resources L.V., G.T., P.P.M., I.K.,  
550 Data Curation L.V., E.G., J.R.C.; Writing L.V. with feedback from all authors; Supervision  
551 P.P.M and I.K.; Project Administration L.V.; Funding Acquisition L.V., P.P.M, and I.K.

552 **Declaration of Interests**

553 The authors declare no competing interests.

554 **Materials and Correspondence**

555 Please address all inquiries to Dr. Igor Koralnik or Dr. Lavanya Visvabharathy.

556 **References**

- 557 1. Center JCR. Cumulative worldwide Covid-19 cases. <https://coronavirus.jhu.edu/map.html>.  
558 Accessed October 5, 2022.
- 559 2. Syed A, et al. Gastrointestinal pathophysiology of SARS-CoV2 - a literature review. *J*  
560 *Community Hosp Intern Med Perspect*. 2020;10(6):523-8.
- 561 3. Liguori C, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2  
562 infection. *Brain Behav Immun*. 2020;88:11-6.
- 563 4. Higgins V, et al. COVID-19: from an acute to chronic disease? Potential long-term health  
564 consequences. *Crit Rev Clin Lab Sci*. 2020:1-23.
- 565 5. Ladds E, et al. Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients  
566 and draft quality principles for services. *BMC Health Serv Res*. 2020;20(1):1144.
- 567 6. Moghimi N, et al. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2  
568 infection. *Curr Neurol Neurosci Rep*. 2021;21(9):44.
- 569 7. Nalbandian A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-15.
- 570 8. Petersen MS, et al. Long COVID in the Faroe Islands - a longitudinal study among non-  
571 hospitalized patients. *Clin Infect Dis*. 2020.
- 572 9. Ahmed H, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome  
573 and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU  
574 admission: A systematic review and meta-analysis. *J Rehabil Med*. 2020;52(5):jrm00063.
- 575 10. Hampshire A, Trender W., Chamberlain SR, Jolly AE, Grant JE, Patrick F, Mazibuko N,  
576 Williams S, Barnaby JM, Hellyer H, Mehta MA. Cognitive deficits in people who have recovered  
577 from COVID-19. *EClinicalMedicine*. 2021.
- 578 11. Grifoni A, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with  
579 COVID-19 Disease and Unexposed Individuals. *Cell*. 2020;181(7):1489-501 e15.

- 580 12. Toor SM, et al. T-cell responses and therapies against SARS-CoV-2 infection. *Immunology*.  
581 2021;162(1):30-43.
- 582 13. Duan YQ, et al. Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients.  
583 *Curr Med Sci*. 2020;40(4):618-24.
- 584 14. McMahan K, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*.  
585 2021;590(7847):630-4.
- 586 15. Fan YY, et al. Characterization of SARS-CoV-specific memory T cells from recovered  
587 individuals 4 years after infection. *Arch Virol*. 2009;154(7):1093-9.
- 588 16. Graham EL, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized  
589 Covid-19 "long haulers". *Ann Clin Transl Neurol*. 2021;8(5):1073-85.
- 590 17. Sudre CH, et al. Attributes and predictors of long COVID. *Nat Med*. 2021;27(4):626-31.
- 591 18. Tang E, et al. Validation of the Patient-Reported Outcomes Measurement Information System  
592 (PROMIS)-57 and -29 item short forms among kidney transplant recipients. *Qual Life Res*.  
593 2019;28(3):815-27.
- 594 19. Weintraub S, et al. Cognition assessment using the NIH Toolbox. *Neurology*. 2013;80(11 Suppl  
595 3):S54-64.
- 596 20. Dangi T, et al. Cross-protective immunity following coronavirus vaccination and coronavirus  
597 infection. *J Clin Invest*. 2021.
- 598 21. Meckiff BJ, et al. Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells  
599 in COVID-19. *Cell*. 2020;183(5):1340-53 e16.
- 600 22. Sledzinska A, et al. Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent  
601 Acquisition of Cytotoxic Function by CD4(+) T Cells. *Immunity*. 2020;52(1):151-66 e6.
- 602 23. Sant AJ, et al. Distinct and complementary roles of CD4 T cells in protective immunity to  
603 influenza virus. *Curr Opin Immunol*. 2018;53:13-21.
- 604 24. Sanchez-Martinez A, et al. Cytotoxic CD4(+) T-cells during HIV infection: Targets or weapons?  
605 *J Clin Virol*. 2019;119:17-23.

- 606 25. Koutsakos M, et al. Integrated immune dynamics define correlates of COVID-19 severity and  
607 antibody responses. *Cell Rep Med.* 2021;2(3):100208.
- 608 26. Chen H, et al. Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS)  
609 coronavirus in recovered SARS patients and healthy individuals. *J Immunol.* 2005;175(1):591-8.
- 610 27. Velazquez-Salinas L, et al. The Role of Interleukin 6 During Viral Infections. *Front Microbiol.*  
611 2019;10:1057.
- 612 28. Boyette LB, et al. Phenotype, function, and differentiation potential of human monocyte subsets.  
613 *PLoS One.* 2017;12(4):e0176460.
- 614 29. Meya DB, et al. Monocyte Phenotype and IFN-gamma-Inducible Cytokine Responses Are  
615 Associated with Cryptococcal Immune Reconstitution Inflammatory Syndrome. *J Fungi (Basel).*  
616 2017;3(2).
- 617 30. Qiao Z, et al. Proteomic study of hepatocellular carcinoma using a novel modified aptamer-based  
618 array (SOMAscan) platform. *Biochim Biophys Acta Proteins Proteom.* 2017;1865(4):434-43.
- 619 31. Timsina J, et al. Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers  
620 Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach. *J*  
621 *Alzheimers Dis.* 2022;89(1):193-207.
- 622 32. George MJ, et al. Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-  
623 Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform. *J Am*  
624 *Heart Assoc.* 2020;9(12):e015628.
- 625 33. Gold L, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS*  
626 *One.* 2010;5(12):e15004.
- 627 34. Parolo S, et al. Combined use of protein biomarkers and network analysis unveils deregulated  
628 regulatory circuits in Duchenne muscular dystrophy. *PLoS One.* 2018;13(3):e0194225.
- 629 35. Matkovic R, et al. TASOR epigenetic repressor cooperates with a CNOT1 RNA degradation  
630 pathway to repress HIV. *Nat Commun.* 2022;13(1):66.

- 631 36. Hirschtick JL, et al. Population-based estimates of post-acute sequelae of SARS-CoV-2 infection  
632 (PASC) prevalence and characteristics. *Clin Infect Dis*. 2021.
- 633 37. Havervall S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-  
634 19 Among Health Care Workers. *JAMA*. 2021;325(19):2015-6.
- 635 38. Weiskopf D, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients  
636 with acute respiratory distress syndrome. *Sci Immunol*. 2020;5(48).
- 637 39. Sekine T, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild  
638 COVID-19. *Cell*. 2020;183(1):158-68 e14.
- 639 40. Rasa S, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome  
640 (ME/CFS). *J Transl Med*. 2018;16(1):268.
- 641 41. Klingenstein M, et al. Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose and  
642 Olfactory Bulb. *Cells Tissues Organs*. 2020;209(4-6):155-64.
- 643 42. Dangi T, et al. Combining spike- and nucleocapsid-based vaccines improves distal control of  
644 SARS-CoV-2. *Cell Rep*. 2021;36(10):109664.
- 645 43. Kantonen J, et al. Neuropathologic features of four autopsied COVID-19 patients. *Brain Pathol*.  
646 2020;30(6):1012-6.
- 647 44. Heming M, et al. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and  
648 Dedifferentiated Monocytes in Cerebrospinal Fluid. *Immunity*. 2021;54(1):164-75 e6.
- 649 45. Schweitzer F, et al. Cerebrospinal Fluid Analysis Post-COVID-19 Is Not Suggestive of Persistent  
650 Central Nervous System Infection. *Ann Neurol*. 2022;91(1):150-7.
- 651 46. Myasoedova E, et al. Is the incidence of rheumatoid arthritis rising?: results from Olmsted  
652 County, Minnesota, 1955-2007. *Arthritis Rheum*. 2010;62(6):1576-82.
- 653 47. Al-Aly Z, et al. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*.  
654 2021;594(7862):259-64.
- 655 48. Boersma P, et al. Prevalence of Multiple Chronic Conditions Among US Adults, 2018. *Prev*  
656 *Chronic Dis*. 2020;17:E106.

- 657 49. Alter G, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in  
658 humans. *Nature*. 2021.
- 659 50. Elyanow R, et al. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and  
660 correlates with neutralizing antibody titers and disease severity. *medRxiv*. 2021.
- 661 51. Good-Jacobson KL, and Shlomchik MJ. Plasticity and heterogeneity in the generation of memory  
662 B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. *J*  
663 *Immunol*. 2010;185(6):3117-25.
- 664 52. Baumjohann D, et al. Persistent antigen and germinal center B cells sustain T follicular helper  
665 cell responses and phenotype. *Immunity*. 2013;38(3):596-605.
- 666 53. Van Elslande J, et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-  
667 2 infected patients up to eight months after infection. *J Clin Virol*. 2021;136:104765.
- 668 54. Tan JT, et al. 4-1BB ligand, a member of the TNF family, is important for the generation of  
669 antiviral CD8 T cell responses. *J Immunol*. 1999;163(9):4859-68.
- 670 55. Derhovanessian E, et al. Infection with cytomegalovirus but not herpes simplex virus induces the  
671 accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. *J Gen Virol*. 2011;92(Pt  
672 12):2746-56.
- 673 56. Strutt TM, et al. Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses  
674 against Influenza. *J Immunol*. 2016;197(8):3260-70.
- 675 57. Diehl S, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. *Immunity*.  
676 2000;13(6):805-15.
- 677 58. Channappanavar R, and Perlman S. Pathogenic human coronavirus infections: causes and  
678 consequences of cytokine storm and immunopathology. *Semin Immunopathol*. 2017;39(5):529-  
679 39.
- 680 59. Wu W, et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response  
681 during an acute retrovirus infection. *Sci Rep*. 2015;5:10501.



- 682 60. Shin H, et al. Viral antigen and extensive division maintain virus-specific CD8 T cells during  
683 chronic infection. *J Exp Med.* 2007;204(4):941-9.
- 684 61. Barnstorf I, et al. Chronic virus infection compromises memory bystander T cell function in an  
685 IL-6/STAT1-dependent manner. *J Exp Med.* 2019;216(3):571-86.
- 686 62. Rosen SF, et al. Increased pain sensitivity and decreased opioid analgesia in T-cell-deficient mice  
687 and implications for sex differences. *Pain.* 2019;160(2):358-66.
- 688 63. Wang T, et al. Transcriptomic profiling of peripheral blood CD4(+) T-cells in asthmatics with  
689 and without depression. *Gene.* 2015;565(2):282-7.
- 690 64. Garber C, et al. T cells promote microglia-mediated synaptic elimination and cognitive  
691 dysfunction during recovery from neuropathogenic flaviviruses. *Nat Neurosci.* 2019;22(8):1276-  
692 88.
- 693 65. Clark MC, and Stein A. CD33 directed bispecific antibodies in acute myeloid leukemia. *Best  
694 Pract Res Clin Haematol.* 2020;33(4):101224.
- 695 66. Pallmer K, et al. NK cells negatively regulate CD8 T cells via natural cytotoxicity receptor  
696 (NCR) 1 during LCMV infection. *PLoS Pathog.* 2019;15(4):e1007725.
- 697 67. Correale J, and Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple  
698 sclerosis. *J Neuroimmunol.* 2008;195(1-2):121-34.
- 699 68. Cho JH, et al. Calcineurin-dependent negative regulation of CD94/NKG2A expression on naive  
700 CD8+ T cells. *Blood.* 2011;118(1):116-28.
- 701 69. Zheng M, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol  
702 Immunol.* 2020;17(5):533-5.
- 703 70. Palacio N, et al. Early type I IFN blockade improves the efficacy of viral vaccines. *J Exp Med.*  
704 2020;217(12).
- 705 71. Roederer M, et al. SPICE: exploration and analysis of post-cytometric complex multivariate  
706 datasets. *Cytometry A.* 2011;79(2):167-74.




Figure 1

707 **Figure 1: Study design and clinical data**

708 A.) Study design, including clinical and immunological data collection. B.) Demographic table  
709 for Neuro-PASC, COVID convalescent, and healthy control subjects. C.) PROMIS-57 patient-  
710 reported survey T scores for Neuro-PASC patients (n=36) and COVID convalescents (n=13). D.)  
711 NIH Toolbox cognitive T scores for Neuro-PASC patients (n=55). Horizontal black line  
712 represents the U.S. national average T score of 50; *p* values relative to demographic-matched US  
713 national average by one sample Wilcoxon signed rank test. \**p*<0.05, \*\*\**p*<0.005, \*\*\*\**p*<0.0001  
714 by two-tailed Student's *t* test.




Figure 2

715 **Figure 2: T cells from Neuro-PASC patients have elevated responses to SARS-CoV-2**  
716 **Nucleocapsid and Membrane proteins compared to COVID convalescents.**

717 A.) Unvaccinated Neuro-PASC patients and healthy COVID convalescents display similar IFN- $\gamma$   
718 responses to SARS-CoV-2 S peptides, but Neuro-PASC patients have enhanced N- and M  
719 peptide-specific responses. B.) Diagram of sub pools derived from N protein (N1-N3, top) and  
720 further subdivision of the N3 peptide pools into 5 sub pools (A-E, bottom). C.) Neuro-PASC T  
721 cells have enhanced IFN- $\gamma$  responses to the C-terminal region of the N protein (N3) compared to  
722 control groups. D.) Neuro-PASC T cells are more highly reactive to certain regions of the C-  
723 terminal domain of N protein, particularly amino acids 309-346, of the SARS-CoV-2  
724 Nucleocapsid protein compared with COVID convalescents. E.) Mapping of TCR sequences to  
725 SARS-CoV-2 Nucleocapsid peptide reveals enhanced N3-specific clonal expansion in Neuro-  
726 PASC patients. F.) Spike RBD antibody response quantification for all groups. G.) Influenza A  
727 hemagglutinin (HA) antibody responses for all groups. +ctrl = plasma from patients who  
728 received the Influenza vaccine within 3 weeks before sample collection. Vaccinated individuals  
729 were included in CC samples for Fig. 2A-D for N and M-specific responses, as SARS-CoV-2  
730 vaccination does not impact T cell responses to viral proteins other than Spike. TCR antigen  
731 specificity was identified using the immuneCODE database from Adaptive Biotechnologies.  
732 Horizontal black line in F-G = limit of detection. Data representative of 10 experiments with all  
733 conditions plated in duplicate. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.005$ , \*\*\*\* $p < 0.0001$  by one-way  
734 ANOVA with Tukey's posttest (A,C, F) or t Test with Welch's correction (D, E).




Figure 3

735 **Figure 3: Virus-specific Tfh cell activation and CD4<sup>+</sup> T cell effector functions differ**  
736 **between Neuro-PASC patients and COVID convalescents.**

737 A.) CD4<sup>+</sup> Tfh cells from Neuro-PASC patients display reciprocal activation patterns to COVID  
738 convalescents in response to Spike and Nucleocapsid peptides. B.) Quantification of AIM<sup>+</sup> Tfh  
739 cell activation to Spike, Nucleocapsid, and Membrane peptides. C.) Anti-SARS-CoV-2  
740 Nucleocapsid IgG endpoint titers for Neuro-PASC, COVID convalescents, and healthy controls  
741 shown in B. D.) CD4<sup>+</sup> T cells from Neuro-PASC patients express less IL-6 and TNF- $\alpha$  in  
742 response to N peptides compared with COVID convalescents. E.) Quantification of cytokine  
743 production from D. F.) CD4<sup>+</sup> T cells from Neuro-PASC patients have enhanced  
744 polyfunctionality and granzyme production after Spike peptide stimulation compared with  
745 COVID convalescents. G.) Expression of cytolytic effector molecules in CD4<sup>+</sup> T cells after S  
746 peptide stimulation. H.) Heatmap quantifying polyfunctionality in different categories of  
747 cytokine production between groups. All data for S pool obtained from unvaccinated individuals;  
748 data for N and M pools obtained from some vaccinated healthy COVID convalescent and healthy  
749 control subjects. Data combined from 6 independent experiments with the indicated n values.  
750 \*p<0.05, \*\*p<0.01, \*\*\*p<0.005 using one-way ANOVA with Bonferroni's posttest (B, C); two-  
751 tailed Student's t Test with Welch's correction (E, F) or a Permutation test (G). All pie graphs  
752 are background subtracted (unstimulated condition; Fig. S7A).




Figure 4



753 **Figure 4: Altered CD8<sup>+</sup> memory T cell activation and function in Neuro-PASC**

754 A.) CD8<sup>+</sup> TEM from Neuro-PASC patients show decreased activation after stimulation with  
755 viral peptides. B.) Quantification of CD8<sup>+</sup> TEM cell activation after S, N, and M peptide  
756 stimulation. C.) CD8<sup>+</sup> TEMRA cells accumulate significantly in PBMC from Neuro-PASC  
757 patients compared to control groups. D.) CD8<sup>+</sup> TEMRA cells from Neuro-PASC patients are less  
758 activated by viral peptides compared with COVID convalescents. E.) Quantification of CD8<sup>+</sup>  
759 TEMRA cell activation. F-G.) CD8<sup>+</sup> TEM from Neuro-PASC patients have enhanced IL-6  
760 production after S and N peptide stimulation compared to COVID convalescents on a per-cell  
761 basis as determined by mean fluorescence intensity (MFI). H.) Spike-specific CD8<sup>+</sup> TEM  
762 express more TNF- $\alpha$  or granzyme B in COVID convalescents while those from Neuro-PASC  
763 patients are biased toward IL-6 and Perforin expression. All data for S pool obtained from  
764 unvaccinated individuals; data for N and M pools obtained from some vaccinated healthy  
765 COVID convalescent and healthy control subjects. Data combined from 5 independent  
766 experiments with the indicated n values. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005 using two-tailed  
767 Student's t test with Welch's correction (B, C, E, G) or Permutation test (H). All pie graphs show  
768 data after subtracting background (unstimulated condition; Fig. S7 C, E).





Figure 5


769 **Figure 5: Correlation of cognitive and psychiatric clinical measures with virus-specific**  
770 **immune responses in Neuro-PASC patients**

771 A.) T cell production of IFN- $\gamma$  against the C-terminal region of N protein is negatively correlated  
772 with self-reported cognition scores (top) and positively correlated with anxiety scores (bottom) in  
773 Neuro-PASC patients. B.) Correlation matrix showing significant positive (blue) or negative  
774 (red) links between adaptive immune responses and clinical parameters in Neuro-PASC patients.  
775 C.) Neuro-PASC patients with high Pain Interference scores express more IL-6 from CD8<sup>+</sup> T  
776 cells in response to S peptides. D.) Heatmap representing data in (C). E.) Neuro-PASC patients  
777 with high depression scores have CD8<sup>+</sup> TEM that express higher levels of cytolytic effector  
778 molecules in response to S peptides. F.) Heatmap representing data in (E). G.) Spike-specific  
779 CD8<sup>+</sup> TCM from Neuro-PASC patients with high executive function cognitive scores express  
780 less granzyme M compared with those with low scores. H.) Heatmap of data in G. Data  
781 representative of 5 independent experiments with n=39-51 for correlation data analysis (A-B)  
782 and n=8-9 NP subjects per quartile for SPICE analysis (C-H). Correlations calculated using  
783 simple linear regression (A) or nonparametric Spearman rank correlations (B). All pie graphs are  
784 background subtracted (unstimulated conditions). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.001 using  
785 Permutation tests.


**A. Immunoregulatory Interactions-  
Lymphoid:Non-lymphoid cell**



**B.**



**C.**



**Figure 6**

786 **Figure 6: Neuro-PASC patients have elevated levels of immunoregulatory proteins in**  
787 **plasma that are correlated with symptom severity and cognitive dysfunction.**

788 A.) Gene set enrichment analysis (GSEA) of proteomic data demonstrating elevations in  
789 immunoregulatory pathway-related proteins (top left panel) in Neuro-PASC patients and  
790 elevated pro-inflammatory and antiviral pathway-related proteins (top right, bottom panels) in  
791 healthy COVID convalescents. List of proteins analyzed in each pathway found in Tables S6-S9.  
792 B.) Comparison of concentrations of individual immunoregulatory (top) and TASOR antiviral  
793 pathway-associated proteins (bottom) between Neuro-PASC patients and healthy COVID  
794 convalescents. C.) Patient-reported outcomes of symptom severity and cognitive metrics are  
795 significantly correlated with expression levels of immunoregulatory proteins (left) and TASOR  
796 pathway proteins (right). RFU: relative fluorescence units. FDR: false discovery rate. NES:  
797 normalized enrichment score. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.005$ ; \*\*\*\* $p < 0.0001$  by Student's t test  
798 (B) or Pearson correlation (C).